|
Cost-effectiveness analysis (CEA)
|
298 (62.5)
|
|
Cost-minimization analysis (CMA)
|
78 (16.4)
|
|
Cost-utility analysis (CUA)
|
73 (15.3)
|
|
Cost-benefit analysis (CBA)
|
28 (5.9)
|
|
Health research activities
| |
|
Prevention of disease and conditions, and promotion of well-being
|
83 (17.4)
|
|
Medically oriented (e.g. chemoprevention, vaccines)
|
78 (16.4)
|
|
Education/behaviour
|
5 (1.0)
|
|
Detection, screening and diagnosis
|
53 (11.1)
|
|
Screening
|
48 (10.1)
|
|
Resources and procedures
|
5 (1.0)
|
|
Treatments and therapeutic interventions
|
334 (70.0)
|
|
Medically oriented (e.g. pharmaceuticals)
|
263 (55.1)
|
|
Devices and procedures
|
33 (6.9)
|
|
Surgery
|
28 (5.9)
|
|
Education/behaviour
|
10 (2.1)
|
|
Rehabilitation
|
7 (1.5)
|
|
Methods
| |
|
Decision analysis
|
162 (34.0)
|
|
Observational studies
|
111 (23.3)
|
|
Not explicit
|
88 (18.4)
|
|
Markov or other simulation models
|
74 (15.5)
|
|
Clinical trials
|
42 (8.8)
|
|
Perspective adopted
| |
|
Healthcare system
|
201 (42.1)
|
|
Non explicit
|
121 (25.4)
|
|
Hospital
|
93 (19.5)
|
|
Society
|
59 (12.4)
|
|
Others
|
3 (0.6)
|
|
Costs
| |
|
Direct
|
404 (84.7)
|
|
Direct and indirect
|
73 (15.3)
|
|
Cost information
| |
|
Explicit
|
359 (75.3)
|
|
Non explicit
|
118 (24.7)
|
|
Funding source
| |
|
Non explicit
|
210 (44.0)
|
|
For profit
|
205 (43.0)
|
|
Non for profit
|
62 (13.0)
|
|
Affiliation of the first author
| |
|
Hospital
|
243 (50.9)
|
|
Private (e.g. consulting, pharmaceutical industry)
|
99 (20.7)
|
|
University
|
56 (11.7)
|
|
Administration
|
55 (11.5)
|
|
Primary care
|
17 (3.6)
|
|
Non explicit
|
7 (1.5)
|
|
Recommendations
| |
|
Yes
|
392 (82.2)
|
|
No
|
85 (17.8)
|
